Deals
Aspen to Buy Anesthetics From AstraZeneca for $520 Million
- South African drugmaker will also make sales-related payments
- Deal comes after Aspen secured 3 billion euros in funding
This article is for subscribers only.
Aspen Pharmacare Holdings Ltd. agreed to buy anesthetics medicines from AstraZeneca Plc for at least $520 million, the first acquisition by Africa’s largest generic-drugs maker since securing new funding.
The South African company will also pay AstraZeneca royalties and as much as $250 million in additional sales-based installments over the next two years, Durban-based Aspen said in a statement on Thursday. Aspen will gain seven established drugs sold in more than 100 countries that generate revenue of $592 million a year.